During the last few years, poly(ADP-ribose)polymerase (PARP) proteins became a very popular target for anticancer treatment. Many PARP inhibitors have been generated and tested by pharmacological industry. However, most of them were designed to disrupt the DNA-dependent PARP1 protein activation pathway and were based on a competition with NAD for a binding site on PARP molecule and, therefore, on disruption of PARP-mediated enzymatic reaction. This limitation resulted in a discovery of mainly nucleotide-like PARP1 inhibitors which may target not only PARP, but also other pathways involving NAD and other nucleotides. Here, we describe a strategy for the identification of PARP inhibitors that target a different pathway, the histone H4-dependent PARP1 activation. Besides the identification of NAD competitors in a small-molecule collection, this approach allows finding novel classes of PARP inhibitors that specifically disrupt H4-based PARP activation.
Springer Nature is developing a new tool to find and evaluate Protocols. Learn more
We thank Dr. M. Einarson of the FCCC Translational Facility for her advice and assistance with small-molecule collection screening experiments, Dr. I. Serebriiskii for helpful discussions, and Dr. M. Robinson for BT474 and HR6 breast cancer cell lines. The research was supported by grants from the National Institutes of Health (R01 DK082623) to A.V.T.
Kim MY, Mauro S, Gevry N, Lis JT, Kraus WL (2004) NAD-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1. Cell 119:803–814PubMedCrossRefGoogle Scholar
Virag L, Szabo C (2002) The therapeutic potential of Poly(ADP-Ribose) Polymerase inhibitors. Pharmacol Rev 54:375–429PubMedCrossRefGoogle Scholar
Haince JF, Poirier GG, Kirkland JB (2003) Nonisotopic methods for determination of poly(ADP-ribose) levels and detection of poly(ADP-ribose) polymerase. Curr Protoc Cell Biol, 18.7.1–18.7.26Google Scholar
Ritter CA et al (2007) Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13:4909–4919PubMedCrossRefGoogle Scholar
Luger K, Rechsteiner TJ, Richmond TJ (1999) Expression and purification of recombinant histones and nucleosome reconstitution. Methods Mol Biol 119:1–16PubMedCrossRefGoogle Scholar
Luger K, Rechsteiner TJ, Richmond TJ (1999) Preparation of nucleosome core particle from recombinant histones. Methods Enzymol 304:3–19PubMedCrossRefGoogle Scholar
Monti D et al (1994) Cell death protection by 3-aminobenzamide and other poly(ADP- ribose)polymerase inhibitors: different effects on human natural killer and lymphokine activated killer cell activities. BBRC 199:525–530PubMedCrossRefGoogle Scholar
Schlicker A et al (1999) 4-Amino-1,8-naphthalimide: a novel inhibitor of poly(ADP-ribose) polymerase and radiation sensitizer. Int J Radiat Biol 75:91–96PubMedCrossRefGoogle Scholar
Banasik M et al (1992) Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J Biol Chem 267:1569–1575PubMedCrossRefGoogle Scholar
Zhang JH et al (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4(2):67–73PubMedCrossRefGoogle Scholar
Iversen PW et al (2006) A comparison of assay performance measures in screening assays: signal window, Z’ factor, and assay variability ratio. J Biomol Screen 11(3):247–252PubMedCrossRefGoogle Scholar
Gottipati P et al (2010) Poly(ADP-Ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res 70:5389–5398PubMedCrossRefGoogle Scholar